TUESDAY, Nov. 26, 2024 (HealthDay News) — Tumor characteristics differ significantly among pediatric and adolescent and young adult (AYA) patients with melanoma, with decreasing incidence rates seen among young patients with cutaneous melanoma, according to a study published online Nov. 15 in the Journal of the American Academy of Dermatology.
2025
Heart Transplant Recipients are More Susceptible to Skin Cancer
Certain factors may contribute to higher occurrences of non-melanoma skin cancer in these patients, according to a novel systemic review.
Predictive tool for melanoma could guide immunotherapy choices
Summary: In previous research, Dana-Farber researchers found that a tumor’s genomic heterogeneity, meaning the tumor’s propensity to develop new mutations, and low genomic ploidy, a measure of the number of chromosomes in the cells, predicts resistance to immune checkpoint blockade with anti-PD-1 therapy.
10-Year Survival Rates Near 80% for Melanoma Patients Responding to Checkpoint Inhibitors
Two sets of 10-year outcome data from large multicenter trials with checkpoint inhibitors for the treatment of advanced melanoma found that more than 40% of treated patients survive 10 years overall, but the 10-year melanoma-free survival approaches 100% in those with a deep response who remain in progression-free survival (PFS) at three years.